Drugs / PA1010
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05468060 | Jun → Dec 2020 | chronic hepatitis B virus infection | Zhejiang Palo Alto Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05019040 | Sep 2021 → Nov 2022 | chronic hepatitis B virus infection | Zhejiang Palo Alto Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PA1010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05468060 ↗ |